CHARLESTON, S.C., April 20, 2012 (GLOBE NEWSWIRE) -- Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCQB:RMCP) announced today that the Israeli Ministry of Health (IMH) has approved the RevVac™ safety syringe for sale and distribution by registering the product in its catalog of approved medical devices. Now that the RevVac™ safety syringe has been licensed in Israel, the Company's exclusive distributor in that country, CeifiT, Ltd. ("CeifiT"), may now accept and fulfill orders from Israel's four national medical centers. The Company is now also permitted to supply the syringes previously pledged to support the IMH's Izhar Project to combat the re-use of contaminated needles.
Ron Wheet, Chief Executive Officer and Chairman of Revolutions Medical, stated, "This is another big step forward for us. The IMH has always had a very progressive attitude towards innovation and safety. The RevVac™ safety syringe fits perfectly with their objectives. We are optimistic that, with this important license, we will be able to see rapid adoption of our product throughout the Israeli healthcare system."
About Revolutions Medical Corporation
Revolutions Medical is a safety medical device and software application company. Its products include the RevVac™ Safety Syringe (FDA cleared), safety blood drawing device, the RevColor™, RevDisplay™, and Rev3D™ software tools that are compatible with standard MRIs and standard Picture Archiving Computer Systems (PACS).
For additional information, please visit Revolutions Medical corporate website: http://www.revolutionsmedical.com/
To be added to the Revolutions Medical investor email list, please email: investment@revolutionsmedical.com with RMCP in the subject line.
FORWARD-LOOKING STATEMENTS
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.